"It was the best of the times, it was the worst of times..."
Our understanding of breast cancer is being transformed
Pharma's incurring bigger and more frequent financial penalties in the US
Healthcare's consuming a larger share of GDP in rich and poor countries alike
Our interactive graphic allows you to view and compare data for each country mentioned in the report and to compare any six of them.
We look at how pharma companies can reach 2020 in a position to benefit from more favourable conditions thereafter - and the most important decisions senior managers will need to make.